The PI3K‐AKT‐mTOR signaling pathway is well known in prostate cancer for its critical role in tumor formation, cancer progression and drug resistance.[25] This potent prolonged inhibition of the AR response and mTOR signaling pathway by UBX‐390 explains its more potent anti‐proliferative and tumor growth inhibitory effects compared to ARV‐110. Here, MTOR is linked to prostate cancer.